Почетна › Лимфом › Тексас › Houston
Kliničke studije za Лимфом u gradu Houston, TX
34 studija za Лимфом traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Тражи се учесникФаза 1
- The University of Texas M D Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Тражи се учесникФаза 3
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Тражи се учесникОпсервациона студија
- Texas Children's Hospital, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Тражи се учесникФаза 1
- University of Texas - MD Anderson Cancer Center, Houston
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Тражи се учесникФаза 2
- UT MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Тражи се учесникФаза 1/2
- Research Site, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Тражи се учесникФаза 3
- Research Site, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Тражи се учесникФаза 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Тражи се учесникФаза 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Тражи се учесникФаза 1/2
- Baylor College of Medicine, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Тражи се учесникФаза 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Тражи се учесникФаза 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Тражи се учесникФаза 1
- UT MD Anderson, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Тражи се учесникФаза 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Тражи се учесникФаза 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Тражи се учесникФаза 1/2
- Dren Investigational Site, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Тражи се учесник
- MD Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Тражи се учесникОпсервациона студија
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Тражи се учесникОпсервациона студија
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Тражи се учесникФаза 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Тражи се учесникФаза 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Studije za Лимфом u drugim gradovima
- Boston, MA34 студија
- New York City, NY33 студија
- Washington, DC23 студија
- Baldwin Park, CA22 студија
- Chicago, IL19 студија
- Durham, NC17 студија
- St. Louis, MO15 студија
- Cleveland, OH13 студија
- Seattle, WA13 студија
- Atlanta, GA13 студија
- Philadelphia, PA13 студија
- Edison, NJ12 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Рак јајника90 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.